MedPath

Genetic Immunity

🇺🇸United States
Ownership
-
Employees
-
Market Cap
-
Website

Clinical Trials

3

Active:0
Completed:3

Trial Phases

2 Phases

Phase 1:1
Phase 2:1

Drug Approvals

0

Drug Approvals

No drug approvals found

This company may not have drug approvals in our database

Clinical Trials

Distribution across different clinical trial phases (2 trials with phase data)• Click on a phase to view related trials

Phase 1
1 (50.0%)
Phase 2
1 (50.0%)

Antiretroviral-Sparing Concept With HIV-specific T Cell Precursors With High Proliferative Capacity (PHPC)

Completed
Conditions
HIV Infection
Interventions
Biological: DermaVir
Biological: Placebo
Drug: HAART
First Posted Date
2009-06-11
Last Posted Date
2013-02-08
Lead Sponsor
Genetic Immunity
Target Recruit Count
16
Registration Number
NCT00918840
Locations
🇮🇹

IRCCS Policlinico S. Matteo, Pavia, Italy

Single DermaVir Immunization in HIV-1 Infected Patients on HAART

Phase 1
Completed
Conditions
HIV Infection
Interventions
Biological: DermaVir
Drug: HAART
First Posted Date
2008-07-10
Last Posted Date
2013-03-26
Lead Sponsor
Genetic Immunity
Target Recruit Count
9
Registration Number
NCT00712530
Locations
🇭🇺

Saint Laszlo Hospital, Budapest, Hungary

Repeated DermaVir Immunizations in HIV-1 Infected Treatment-naïve Patients

Phase 2
Completed
Conditions
HIV Infection
First Posted Date
2008-07-08
Last Posted Date
2020-01-28
Lead Sponsor
Genetic Immunity
Target Recruit Count
36
Registration Number
NCT00711230
Locations
🇩🇪

ifi-Medizin GmbH at the Asklepios Klinik St. Georg, Hamburg, Germany

🇩🇪

ICH Grindel, Hamburg, Germany

🇩🇪

University Medical Center Hamburg-Eppendorf, Hamburg, Germany

News

No news found

MedPath

Empowering clinical research with data-driven insights and AI-powered tools.

© 2025 MedPath, Inc. All rights reserved.